1. Thailand Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Inter Pharma Public Company Limited

Inter Pharma Public Company Limited

IP.BK
Inter Pharma Public Company LimitedTH flagStock Exchange of Thailand
4.52
THB
- -
- -
2.74BMarket Cap
Inter Pharma Public Company Limited
IP.BK
(Stock Exchange of Thailand)

Recent

price

4.52

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.74
0.95
1.04
0.94
1.91
2.86
2.94
3.13
3.62
3.67
Revenue per Share
0.05
0.09
0.12
0.11
0.22
0.22
0.08
0.06
0.2
0.22
Basic EPS, GAAP
0.02
-0.05
0.01
-0.05
-0.59
0.18
-0.04
-0.14
0.27
0.22
Free Cash Flow per Basic Share
0.11
0.08
0.03
0.08
0.01
- -
0.11
0.02
- -
- -
Dividend per Share
0.15
0.22
0.39
0.32
0.53
0.76
0.64
0.68
0.87
0.93
Book Value per Share
0.24
0.32
1.3
0.88
1.49
2.76
2.38
2.28
2.5
2.57
Tangible Book Value per Share
333
333
356
470
475
532
605
605
605
605
Basic Weighted Avg Shares
247
317
371
442
909
1,523
1,781
1,897
2,193
2,223
Sales/Revenue/Turnover
11.58
12.93
16.63
17.4
16.04
11.21
6.14
3.91
8.75
9.37
Operating Margin (%)
1
2
2
6
27
66
98
113
117
119
Depreciation Expense
16
30
43
53
105
119
51
37
122
133
Net Income, GAAP
33.27
27.84
22.68
21.67
19.75
13.23
27.61
30.61
20.5
21.46
Effective Tax Rate (%)
6.36
9.37
11.71
11.88
11.58
7.8
2.85
1.93
5.58
5.99
Profit Margin (%)
65
89
449
257
331
1,017
724
456
468
515
Working Capital
- -
- -
- -
93
189
387
260
233
186
178
LT Debt
79
107
466
486
784
2,116
2,118
2,158
2,299
2,338
Total Equity
- -
29.59
15.95
11.07
13.33
7.79
3.07
2.05
5.85
6.08
Return on Invested Capital (%)
- -
41.06
31.84
20.8
23.18
14.84
5.77
5
11.32
11.34
Return on Capital (%)
- -
47.81
40.31
35.86
52.22
36.3
12.81
9.18
26.06
26.57
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
215
215
199
LT Borrowings
139
124
124
LT Finance Leases
61
62
54
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
605
605
605
Market Capitalization
2,518
2,785
2,446

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,110
1,106
1,161
Cash, Cash Equivalents & STI
303
282
305
Accounts Receivable, Net
351
365
344
Inventories
347
350
385
Total Current Liabilities
621
638
645
Payables & Accruals
379
398
416
ST Debt
215
215
199
Deferred Revenue
9
5
9

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
47.94%
6.54%
Free Cash Flow
- -
162.62%
-296.36%
Net Income, GAAP
- -
52.41%
233.93%
Sales/Revenue/Turnover
- -
42.45%
15.61%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
484
445
436
532
1,897
2025
531
535
556
572
2,193
2026
560
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.01
0.01
- -
0.06
2025
0.04
0.05
0.07
- -
0.2
2026
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.02
- -
- -
0.02
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
VioQuest Pharmaceuticals, Inc. (VOQP)
AgomAb Therapeutics N.V. American Depositary Shares (AGMB)
VistaGen Therapeutics, Inc. (VTGN)
Cell Source, Inc. (CLCS)
Salarius Pharmaceuticals, Inc. (SLRX)
Nuvectis Pharma, Inc. (NVCT)
Business
Inter Pharma Public Company Limited manufactures, imports, distributes and researches healthcare products including dietary supplements, pharmaceuticals, cosmeceuticals, functional foods, cosmetics, medical equipment and aesthetic innovation products for humans; pet healthcare and livestock products such as vaccines, nutraceuticals, shampoos, ear and teeth cleaners, pee pads and animal feeds; and hospital services encompassing treatment for cardiovascular, bone and joint, kidney, obstetrics, gynecology and other specialized diseases, operating through human healthcare, animal healthcare and hospital/clinics segments primarily in Thailand with manufacturing capabilities for solid, liquid and semi-solid dosage forms. The Bangkok-based company, founded in 2006 and headquartered at 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong Sub-District, Bang Rak District, serves retail customers via distributors and holds investment promotion certificates from the Board of Investment for innovative lines like glaucoma eye-drop production. In November 2025, Inter Pharma agreed to acquire an additional 49% stake in Interpharma-ZEAvita Company Limited from Thai Union Ingredients for full 99.99% ownership using internal funds, subject to board approval and expected to close in Q4 2025.